Efficacy and Safety of Imatinib Mesylate in Advanced Gastrointestinal Stromal Tumors
Open accessThe DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Constitutive activation of KIT receptor tyrosine kinase is critical in the pathogenesis of gastrointestinal stromal tumors. Imatinib mesylate, a selective tyrosine kinase inhibitor, has been shown in preclinical models and preliminary clinical studies to have activity against such tumors. METHODS: We conducted an open-label, randomized, multicenter trial to evaluate the activity of imatinib in patients with advanced gastrointestinal stromal tumor. We assessed antitumor response and the safety and tolerability of the drug. Pharmacokinetics were assessed in a subgroup of patients. RESULTS: A total of 147 patients were randomly assigned to receive 400 mg or 600 mg of imatinib daily. Overall, 79 patients (53.7 percent) had a partial response, 41 patients (27.9 percent) had stable disease, and for technical reasons, response could not be evaluated in 7 patients (4.8 percent). No patient had a complete response to the treatment. The median duration of response had not been reached after a median follow-up of 24 weeks after the onset of response. Early resistance to imatinib was noted in 20 patients (13.6 percent). Therapy was well tolerated, although mild-to-moderate edema, diarrhea, and fatigue were common. Gastrointestinal or intraabdominal hemorrhage occurred in approximately 5 percent of patients. There were no significant differences in toxic effects or response between the two doses. Imatinib was well absorbed, with pharmacokinetics similar to those reported in patients with chronic myeloid leukemia. CONCLUSIONS: Imatinib induced a sustained objective response in more than half of patients with an advanced unresectable or metastatic gastrointestinal stromal tumor. Inhibition of the KIT signal-transduction pathway is a promising treatment for advanced gastrointestinal stromal tumors, which resist conventional chemotherapy.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Citations
Cites
Druker, B. J., Talpaz, M., Resta, D. J., Peng, B., Buchdunger, E., Ford, J. M., Lydon, N. B., Kantarjian, H., Capdeville, R., Ohno-Jones, S., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200104053441401 · Cited by 5,243
Self-citationDiagnosis of gastrointestinal stromal tumors: A consensus approach
Fletcher, C. D. M., Berman, J. J., Corless, C., Gorstein, F., Lasota, J., Longley, B. J., Miettinen, M., O'Leary, T. J., Remotti, H., Rubin, B. P., et al. (2002) · Human Pathology · doi:10.1053/hupa.2002.123545 · Cited by 3,419
Self-citationClinical Resistance to STI-571 Cancer Therapy Caused by BCR-ABL Gene Mutation or Amplification
Gorre, M. E., Mohammed, M., Ellwood, K., Hsu, N., Paquette, R., Rao, P. N., & Sawyers, C. L. (2001) · Science · doi:10.1126/science.1062538 · Cited by 3,104
Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells
Druker, B. J., Tamura, S., Buchdunger, E., Ohno, S., Segal, G. M., Fanning, S., Zimmermann, J., & Lydon, N. B. (1996) · Nature Medicine · doi:10.1038/nm0596-561 · Cited by 2,967
Self-citationDruker, B. J., Sawyers, C. L., Kantarjian, H., Resta, D. J., Reese, S. F., Ford, J. M., Capdeville, R., & Talpaz, M. (2001) · New England Journal of Medicine · doi:10.1056/nejm200104053441402 · Cited by 2,713
Self-citationTwo Hundred Gastrointestinal Stromal Tumors: Recurrence Patterns and Prognostic Factors for Survival
DeMatteo, R. P., Lewis, J. J., Leung, D., Mudan, S. S., Woodruff, J. M., & Brennan, M. F. (2000) · Annals of Surgery · doi:10.1097/00000658-200001000-00008 · Cited by 2,554
Joensuu, H., Roberts, P. J., Sarlomo-Rikala, M., Andersson, L. C., Tervahartiala, P., Tuveson, D., Silberman, S. L., Capdeville, R., Dimitrijevic, S., Druker, B., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200104053441404 · Cited by 2,037
Self-citationBuchdunger, E., Cioffi, C. L., Law, N., Stover, D., Ohno-Jones, S., Druker, B. J., & Lydon, N. B. (2000) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)38879-2 · Cited by 1,274
Self-citationvan Oosterom, A. T., Judson, I., Verweij, J., Stroobants, S., di Paola, E. D., Dimitrijevic, S., Martens, M., Webb, A., Sciot, R., Van Glabbeke, M., et al. (2001) · The Lancet · doi:10.1016/s0140-6736(01)06535-7 · Cited by 1,264
Self-citationHeinrich, M. C., Griffith, D. J., Druker, B. J., Wait, C. L., Ott, K. A., & Zigler, A. J. (2000) · Blood · doi:10.1182/blood.v96.3.925 · Cited by 1,071
Self-citation
Research works printed but not linked: 4
- Rubin BP, 2001, Cancer Res, 61, 8118
- Goss GA, 2000, Prog Proc Am Soc Clin Oncol, 19, 599a
- Buchdunger E, 2000, J Pharmacol Exp Ther, 295, 139
- Peng B, 2001, Prog Proc Am Soc Clin Oncol, 20, 71a
Cited by
Items 801–900 of 1,007
Targeted treatments for cirrhosis
Fallowfield, J. A., & Iredale, J. P. (2004) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.8.5.423 · Cited by 68
Álvarez‐Twöse, I., González, P., Morgado, J. M., Jara‐Acevedo, M., Sánchez‐Muñoz, L., Matito, A., Mollejo, M., Órfão, A., & Escribano, L. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.38.9973 · Cited by 70
Shirao, K., Nishida, T., Doi, T., Komatsu, Y., Muro, K., Li, Y., Ueda, E., & Ohtsu, A. (2009) · Investigational New Drugs · doi:10.1007/s10637-009-9306-9 · Cited by 66
Tsuda, H., Morita, D., 木村, 幹., Shinto, E., Ohtsuka, Y., Matsubara, O., Inazawa, J., Tamaki, K., Mochizuki, H., Tamai, S., et al. (2005) · Cancer Science · doi:10.1111/j.1349-7006.2005.00009.x · Cited by 66
Chen, J., Wall, N. R., Kocher, K., Duclos, N., Fabbro, D., Neuberg, D. S., Griffin, J. D., Shi, Y., & Gilliland, D. G. (2004) · Journal of Clinical Investigation · doi:10.1172/jci20673 · Cited by 70
Adult soft tissue sarcomas: Conventional therapies and molecularly targeted approaches
Mocellin, S., Rossi, C. R., Brandes, A. A., & Nitti, D. (2005) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2005.10.003 · Cited by 70
Yoo, C., Ryu, M., Jo, J., Park, I., Ryoo, B., & Kang, Y. (2015) · Cancer Research and Treatment · doi:10.4143/crt.2015.015 · Cited by 65
Turley, R. S., Peng, P. D., Reddy, S. K., Barbas, A. S., Geller, D. A., Marsh, J. W., Tsung, A., Pawlik, T. M., & Clary, B. M. (2011) · Cancer · doi:10.1002/cncr.26650 · Cited by 67
Effect of a proton pump inhibitor on the pharmacokinetics of imatinib
Egorin, M. J., Shah, D. D., Christner, S. M., Yerk, M., Komazec, K. A., Appleman, L. J., Redner, R. L., Miller, B. M., & Beumer, J. H. (2009) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2009.03466.x · Cited by 69
Recent advances in the treatment of gastrointestinal stromal tumors
Serrano, C., & George, S. (2014) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758834014522491 · Cited by 68
Corbo, V., Beghelli, S., Bersani, S., Antonello, D., Talamini, G., Brunelli, M., Capelli, P., Falconi, M., & Scarpa, A. (2011) · Annals of Oncology · doi:10.1093/annonc/mdr048 · Cited by 67
Bioequivalence, safety, and tolerability of imatinib tablets compared with capsules
Nikolova, Z. G., Peng, B., Hubert, M., Seiberling, M., Keller, U., Ho, Y.-Y., SCHRAN, H. F., & Capdeville, R. (2004) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-003-0756-z · Cited by 65
Self-citationde Oliveira, A. T. T., Pinheiro, C. M., Longatto‐Filho, A., Brito, M. J., Martinho, O., Matos, D., Carvalho, A. L., Vazquez, V. D. L., Silva, T. B., Scapulatempo‐Neto, C., et al. (2012) · Journal of Bioenergetics and Biomembranes · doi:10.1007/s10863-012-9408-5 · Cited by 65
GAO, C., Peng, F., & PENG, L. K. (2014) · Neoplasma · doi:10.4149/neo_2014_083 · Cited by 67
Soft Tissue Sarcoma Guidelines
_, _. (2007) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2007.0034 · Cited by 65
Targeted Agents: The Rules of Combination
Kwak, E. L., Clark, J. W., & Chabner, B. A. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-1385 · Cited by 72
Patterns of gene amplification in gastrointestinal stromal tumors (GIST)
Tornillo, L., Duchini, G., Carafa, V., Lugli, A., Dirnhofer, S., Vizio, D. D., Boscaino, A., Russo, R., Tapia, C., Schneider‐Stock, R., et al. (2005) · Laboratory Investigation · doi:10.1038/labinvest.3700284 · Cited by 68
Tailoring Ras-pathway—Inhibitor combinations for cancer therapy
Blum, R., & Kloog, Y. (2005) · Drug Resistance Updates · doi:10.1016/j.drup.2005.11.002 · Cited by 72
Segmental resection of the duodenum for gastrointestinal stromal tumor (GIST)
Mennigen, R. B., Wolters, H. H., Schulte, B., & Pelster, F. W. (2008) · World Journal of Surgical Oncology · doi:10.1186/1477-7819-6-105 · Cited by 69
Nakagomi, N., & Hirota, S. (2007) · Laboratory Investigation · doi:10.1038/labinvest.3700524 · Cited by 64
Joensuu, H., de Braud, F., Coco, P., Pas, T. M. D., Putzu, C., Spreafico, C., Bono, P., Boselli, S., Jalava, T., Laurent, D., et al. (2007) · Annals of Oncology · doi:10.1093/annonc/mdm419 · Cited by 65
Self-citationA HIF-Regulated VHL-PTP1B-Src Signaling Axis Identifies a Therapeutic Target in Renal Cell Carcinoma
Suwaki, N., Vanhecke, E., Atkins, K. M., Graf, M., Swabey, K., Huang, P., Schraml, P., Moch, H., Cassidy, A. M., Brewer, D., et al. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3002004 · Cited by 66
Hasegawa, J., Kanda, T., Hirota, S., Fukuda, M., Nishitani, A., Takahashi, T., Kurosaki, I., Tsutsui, S., Hatakeyama, K., & Nishida, T. (2007) · International Journal of Clinical Oncology · doi:10.1007/s10147-007-0657-y · Cited by 64
Deeks, E. D., & Keating, G. M. (2006) · Drugs · doi:10.2165/00003495-200666170-00007 · Cited by 64
Population-based study of the diagnosis and treatment of gastrointestinal stromal tumours
Bümming, P., Ahlman, H. K., Andersson‐Assarsson, J. C., Meis‐Kindblom, J. M., Kindblom, L.-G., & Nilsson, B. (2006) · British journal of surgery · doi:10.1002/bjs.5350 · Cited by 67
Madani, A., Kemmer, K. A., Sweeney, C. J., Corless, C. L., Ulbright, T. M., Heinrich, M. C., & Einhorn, L. H. (2003) · Annals of Oncology · doi:10.1093/annonc/mdg244 · Cited by 64
Self-citationLoss of RKIP expression is associated with poor survival in GISTs
Martinho, O., Gouveia, A., Silva, P., Pimenta, A. P. A., Reis, R. M., & Lopes, J. M. (2009) · Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin · doi:10.1007/s00428-009-0821-z · Cited by 69
Current management of gastrointestinal stromal tumors – A comprehensive review
Lai, E. C. H., Lau, S. H. Y., & Lau, W. Y. (2012) · International Journal of Surgery · doi:10.1016/j.ijsu.2012.05.007 · Cited by 70
Flaherty, K. T. (2012) · Annual Review of Medicine · doi:10.1146/annurev-med-050410-105655 · Cited by 64
Blay, J. (2010) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2010.11.003 · Cited by 73
Sunitinib in the treatment of gastrointestinal stromal tumor: patient selection and perspectives
Mulet-Margalef, N., & del Muro, X. G. (2016) · OncoTargets and Therapy · doi:10.2147/ott.s101385 · Cited by 70
FOXF1 Defines the Core-Regulatory Circuitry in Gastrointestinal Stromal Tumor
Ran, L., Chen, Y., Sher, J. J., Wong, E. W. P., Murphy, D. A., Zhang, J. Q., Li, D., Denız, K., Sirota, I., Cao, Z., et al. (2017) · Cancer Discovery · doi:10.1158/2159-8290.cd-17-0468 · Cited by 70
Gastrointestinal stromal tumors: past, present, and future
Kitamura, Y. (2008) · Journal of Gastroenterology · doi:10.1007/s00535-008-2200-y · Cited by 65
Imaging of Gastrointestinal Stromal Tumors
Kim, H., Lee, J. M., Choi, S. H., Kim, K. W., Kim, S. H., Lee, J., Han, J. K., & Choi, B. I. (2004) · Journal of Computer Assisted Tomography · doi:10.1097/01.rct.0000138988.23480.db · Cited by 63
Lack of c-kit exon 11 activating mutations in c-KIT/CD117-positive SCLC tumour specimens
Burger, H., den Bakker, M. A., Stoter, G., Verweij, J., & Nooter, K. (2003) · European Journal of Cancer · doi:10.1016/s0959-8049(03)00026-1 · Cited by 67
Miller, J. C., & Thrall, J. H. (2004) · Journal of the American College of Radiology · doi:10.1016/s1546-1440(03)00025-5 · Cited by 72
Willmore‐Payne, C., Holden, J. A., Zhou, L., Tripp, S. R., Wittwer, C. T., & Layfield, L. J. (2004) · American Journal of Clinical Pathology · doi:10.1309/4e6u-yby6-2n2f-ca6n · Cited by 63
Trempat, P., Villalva, C., Laurent, G., Armstrong, F., Delsol, G., Dastugue, N., & Brousset, P. (2003) · Oncogene · doi:10.1038/sj.onc.1206543 · Cited by 63
A paradigm for therapy-induced microenvironmental changes in solid tumors leading to drug resistance
Yu, J., Kerbel, R. S., & Coomber, B. L. (2002) · Differentiation · doi:10.1046/j.1432-0436.2002.700913.x · Cited by 71
Molecular prescreening to select patient population in early clinical trials
Rodon, J. A., Saura, C., Dienstmann, R., Vivancos, A. P., y Cajal, S. R., Baselga, J. M., & Tabernero, J. M. (2012) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2012.48 · Cited by 68
Chiorean, E. G., Sweeney, C. J., Youssoufian, H., Qin, A., Dontabhaktuni, A., Loizos, N., Nippgen, J., & Amato, R. J. (2014) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-014-2389-9 · Cited by 62
Current management and prognostic features for gastrointestinal stromal tumor (GIST)
Lamba, G. S., Gupta, R., Lee, B., Ambrale, S., & Liu, D. (2012) · Experimental Hematology and Oncology · doi:10.1186/2162-3619-1-14 · Cited by 63
Japanese Study Group on GIST, Nishida, T., Takahashi, T., Nishitani, A., Doi, T., Shirao, K., Komatsu, Y., Nakajima, K., & Hirota, S. (2009) · International Journal of Clinical Oncology · doi:10.1007/s10147-008-0822-y · Cited by 63
Stewart, D. R., Corless, C. L., Rubin, B. P., Heinrich, M. C., Messiaen, L. M., Kessler, L., Zhang, P. J., & Brooks, D. G. (2007) · Journal of Medical Genetics · doi:10.1136/jmg.2006.043075 · Cited by 62
Self-citationReview article: the biology, diagnosis and management of gastrointestinal stromal tumours
Iorio, N., Sawaya, R. A., & Friedenberg, F. K. (2014) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.12761 · Cited by 67
Probabilistic Analysis and Computationally Expensive Models: Necessary and Required?
Griffin, S. C., Claxton, K., Hawkins, N., & Sculpher, M. (2006) · Value in Health · doi:10.1111/j.1524-4733.2006.00107.x · Cited by 78
Kim, K.-H., Kim, M., Jung, G., Kim, S., Jang, J.-S., & Kwon, H. (2012) · World Journal of Surgical Oncology · doi:10.1186/1477-7819-10-230 · Cited by 62
Yeh, C., Chen, M., Chen, Y., Yang, C., Yen, C., Tzen, C., Chen, L., & Chen, J. (2017) · Oncotarget · doi:10.18632/oncotarget.17310 · Cited by 62
Sleijfer, S., Wiemer, E. A. C., Seynaeve, C., & Verweij, J. (2007) · The Oncologist · doi:10.1634/theoncologist.12-6-719 · Cited by 62
Chemical proteomics reveals target selectivity of clinical Jak inhibitors in human primary cells
Eberl, H. C., Werner, T., Reinhard, F. B. M., Lehmann, S., Thomson, D. W., Chen, P., Zhang, C., Rau, C., Muelbaier, M., Drewes, G., et al. (2019) · Scientific Reports · doi:10.1038/s41598-019-50335-5 · Cited by 69
Isotani, M., Yamada, O., Lachowicz, J. L., Tamura, K., Yagihara, H., Fujino, Y., Ono, K., Washizu, T., & Bonkobara, M. (2009) · British Journal of Haematology · doi:10.1111/j.1365-2141.2009.07926.x · Cited by 61
Heinicke, T., Wardelmann, E., Sauerbruch, T., Tschampa, H. J., Glasmacher, A. G., & PALMEDO, H. (2005) · PubMed · Cited by 61
Ladewski, L. A., Belknap, S. M., Nebeker, J. R., Sartor, O. A., Lyons, E. A., Kuzel, T. C., Tallman, M. S., Raisch, D. W., Auerbach, A. R., Schumock, G. T., et al. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.04.537 · Cited by 61
Wang, X., MacLennan, G. T., Antonio Lopez-beltran, B., & Liang Cheng, C. (2007) · Applied immunohistochemistry & molecular morphology · doi:10.1097/01.pai.0000213106.12731.d7 · Cited by 61
Pantaleo, M. A., Tarantino, G., Agostinelli, C., Urbini, M., Nannini, M., Saponara, M., Castelli, C., Stacchiotti, S., Fumagalli, E. R., Gatto, L., et al. (2019) · OncoImmunology · doi:10.1080/2162402x.2019.1617588 · Cited by 62
Emerging Therapies for Liver Fibrosis
Fowell, A. J., & Iredale, J. P. (2006) · Digestive Diseases · doi:10.1159/000090320 · Cited by 64
Widmer, N., Béguin, A., Rochat, B., Buclin, T., Kovacsovics, T. J., Duchosal, M. A., Leyvraz, S., Rosselet, A., Biollaz, J., & Decosterd, L. A. (2004) · Journal of Chromatography B · doi:10.1016/j.jchromb.2004.01.006 · Cited by 61
Conventional and novel PET tracers for imaging in oncology in the era of molecular therapy
Pantaleo, M. A., Nannini, M., Maleddu, A., Fanti, S., Ambrosini, V., Nanni, C., Boschi, S., & Biasco, G. (2007) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2007.10.001 · Cited by 70
Willmore‐Payne, C., Holden, J. A., & Layfield, L. J. (2006) · Human Pathology · doi:10.1016/j.humpath.2006.02.004 · Cited by 61
Bono, P., Krause, A., von Mehren, M., Heinrich, M. C., Blanke, C. D., Dimitrijević, S., Demetri, G. D., & Joensuu, H. (2004) · Blood · doi:10.1182/blood-2003-10-3443 · Cited by 62
Self-citationTargeting the molecular pathophysiology of gastrointestinal stromal tumors with imatinib
Demetri, G. D. (2002) · Hematology/Oncology Clinics of North America · doi:10.1016/s0889-8588(02)00052-7 · Cited by 62
Self-citationOcular Toxicity of Targeted Anticancer Agents
Fortes, B. H., Tailor, P. D., & Dalvin, L. A. (2021) · Drugs · doi:10.1007/s40265-021-01507-z · Cited by 64
Applications of molecular techniques to fine-needle aspiration biopsy
Krishnamurthy, S. (2007) · Cancer · doi:10.1002/cncr.22489 · Cited by 60
Modern treatment of gastric gastrointestinal stromal tumors
Roggin, K. K. (2012) · World Journal of Gastroenterology · doi:10.3748/wjg.v18.i46.6720 · Cited by 60
Utility of positron emission tomography in sarcomas
Schuetze, S. M. (2006) · Current Opinion in Oncology · doi:10.1097/01.cco.0000228744.49294.12 · Cited by 60
Benjamin, R. S., Schöffski, P., Hartmann, J. T., van Oosterom, A., Bui, B., Duyster, J., Schuetze, S. M., Blay, J., Reichardt, P., Rosen, L. S., et al. (2010) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-010-1431-9 · Cited by 60
Wolff, N. C., Randle, D. E., Egorin, M. J., Minna, J. D., & Ilaria, R. L. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-0957-03 · Cited by 60
Gastrointestinal Stromal Tumors
Balachandran, V. P., & DeMatteo, R. P. (2014) · Advances in Surgery · doi:10.1016/j.yasu.2014.05.014 · Cited by 60
Klug, L. R., Kent, J. D., & Heinrich, M. C. (2018) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2018.06.016 · Cited by 68
Self-citationA prospective analysis of imatinib‐induced c‐kit modulation in ovarian cancer
Posadas, E. M., Kwitkowski, V. E., Kotz, H. L., Espina, V. A., Minasian, L. M., Tchabo, N. E., Premkumar, A., Hussain, M. M., Chang, R., Steinberg, S. M., et al. (2007) · Cancer · doi:10.1002/cncr.22757 · Cited by 60
Serum vascular endothelial growth factor as a tumour marker in soft tissue sarcoma
Hayes, A. J., Mostyn-Jones, A., Koban, M. U., A’Hern, R., Burton, P., & Thomas, J. M. (2004) · British journal of surgery · doi:10.1002/bjs.4398 · Cited by 60
VEGF inhibitors for the treatment of neovascular age-related macular degeneration
Barakat, M. R., & Kaiser, P. (2009) · Expert Opinion on Investigational Drugs · doi:10.1517/13543780902855316 · Cited by 60
Corbin, A. S., Demehri, S., Griswold, I. J., Wang, Y., Metcalf, C. A., Sundaramoorthi, R., Shakespeare, W. C., Snodgrass, J. T., Wardwell, S., Dalgarno, D. C., et al. (2005) · Blood · doi:10.1182/blood-2004-12-4771 · Cited by 60
Self-citationBachireddy, P., Bendapudi, P. K., & Felsher, D. W. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-0534 · Cited by 66
Detection of Resistance to Imatinib by Metabolic Profiling
Serkova, N. J., & Boros, L. (2005) · American Journal of PharmacoGenomics · doi:10.2165/00129785-200505050-00002 · Cited by 59
Berglund, E., Akçakaya, P., Berglund, D., Karlsson, F., Vukojević, V. B., Lee, L., Bogdanović, D., Lui, W., Larsson, C., Zedenius, J., et al. (2014) · Experimental Cell Research · doi:10.1016/j.yexcr.2014.05.003 · Cited by 60
Thymic Tumors: Relevant Molecular Data in the Clinic
Girard, N. (2010) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e3181f209b9 · Cited by 60
Pharmacological Inhibition of KIT Activates MET Signaling in Gastrointestinal Stromal Tumors
Cohen, N. A., Zeng, S., Seifert, A. M., Kim, T. S., Sorenson, E. C., Greer, J. B., Beckman, M. J., Santamaria‐Barria, J. A., Crawley, M. H., Green, B. L., et al. (2015) · Cancer Research · doi:10.1158/0008-5472.can-14-2564 · Cited by 60
Kartha, R. V., & Sundram, U. N. (2007) · Modern Pathology · doi:10.1038/modpathol.3800980 · Cited by 62
Pancreatic cancer treatment and research: an international expert panel discussion
Tempero, M. A., Berlin, J. D., Ducreux, M. P., Haller, D. G., Harper, P., Khayat, D., Schmoll, H., Sobrero, A. F., & Cutsem, E. V. (2011) · Annals of Oncology · doi:10.1093/annonc/mdq545 · Cited by 59
Bibliometric analysis of the top-cited gastroenterology and hepatology articles
Azer, S. A., & Azer, S. (2016) · BMJ Open · doi:10.1136/bmjopen-2015-009889 · Cited by 66
Lin, Y.-L., & Roux, B. (2013) · Journal of the American Chemical Society · doi:10.1021/ja405939x · Cited by 58
Aoto, K., Ito, K., & Aoki, S. (2018) · Oncotarget · doi:10.18632/oncotarget.26124 · Cited by 65
Sunitinib for imatinib-resistant GIST
Joensuu, H. (2006) · The Lancet · doi:10.1016/s0140-6736(06)69489-0 · Cited by 59
Self-citationDEGROOT, J., Plaza-Menacho, I., Schepers, H., Drenth-Diephuis, L. J., Osinga, J. A. J., PLUKKER, J., Links, T. P., Eggen, B. J. L., & Hofstra, R. M. W. (2006) · Surgery · doi:10.1016/j.surg.2005.10.019 · Cited by 59
Hunt, G. C., Rader, A. E., & Faigel, D. O. (2003) · Gastrointestinal Endoscopy · doi:10.1067/mge.2003.146 · Cited by 59
Inherited predisposition to cancer: A historical overview
Lynch, H. T., Shaw, T. G., & Lynch, J. F. (2004) · American Journal of Medical Genetics Part C Seminars in Medical Genetics · doi:10.1002/ajmg.c.30026 · Cited by 69
BNP as a marker of the heart failure in the treatment of imatinib mesylate
Park, Y. H., Park, H. J., Kim, B. S., Ha, E., Jung, K. H., Yoon, S. H., Yim, S. V., & Chung, J. (2006) · Cancer Letters · doi:10.1016/j.canlet.2005.11.014 · Cited by 63
Willmore‐Payne, C., Layfield, L. J., & Holden, J. A. (2005) · Cancer · doi:10.1002/cncr.21064 · Cited by 59
Serrano, C., Leal, A., Kuang, Y., Morgan, J. A., Barysauskas, C. M., Phallen, J. A., Triplett, O., Mariño‐Enríquez, A., Wagner, A. J., Demetri, G. D., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-2150 · Cited by 59
Self-citationGastrointestinal stromal tumor: Recent advances in pathology and genetics
Yamamoto, H., & Oda, Y. (2014) · Pathology International · doi:10.1111/pin.12230 · Cited by 59
Liu, Y., Perdreau, S. A., Chatterjee, P., Wang, L., Kuan, S., & Duensing, A. U. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-1935 · Cited by 58
Functional Characterization of Human Cancer-Derived TRKB Mutations
Geiger, T. R., Song, J.-Y., Rosado, A., & Peeper, D. S. (2011) · PLoS ONE · doi:10.1371/journal.pone.0016871 · Cited by 57
Ochs, M. F., Rink, L. A., Tarn, C., Mburu, S., Taguchi, T., Eisenberg, B. L., & Godwin, A. K. (2009) · Cancer Research · doi:10.1158/0008-5472.can-09-1709 · Cited by 59
Self-citationTargeted therapy of cancer: new roles for pathologists in identifying GISTs and other sarcomas
Antonescu, C. R. (2008) · Modern Pathology · doi:10.1038/modpathol.2008.9 · Cited by 58
Maleddu (2009) · Oncology Reports · doi:10.3892/or_00000361 · Cited by 58
Role of randomized phase III trials in an era of effective targeted therapies
Sharma, M. R., & Schilsky, R. L. (2011) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2011.190 · Cited by 63
Salazar, M., Barata, A., André, S., Venâncio, J., Francisco, I., Cravo, M., & Nobre-Leitão, C. (2006) · Gut · doi:10.1136/gut.2005.086744 · Cited by 58
Kinase inhibitors in the treatment of immune-mediated disease
Kontzias, A., Laurence, A. D. J., Gadina, M., & O’Shea, J. J. (2012) · F1000 Medicine Reports · doi:10.3410/m4-5 · Cited by 59
Gastrointestinal Stromal Tumor: A Clinical Overview
Quek, R. H. H., & George, S. (2009) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2008.11.006 · Cited by 70
Metadata
- Authors
- Demetri, G. D., von Mehren, M., Blanke, C. D., Van den Abbeele, A. D., Eisenberg, B., Roberts, P. J., Heinrich, M. C., Tuveson, D. A., Singer, S., Janicek, M., Fletcher, J. A., Silverman, S. G., Silberman, S. L., Capdeville, R., Kiese, B., Peng, B., Dimitrijevic, S., Druker, B. J., Corless, C., Fletcher, C. D. M., & Joensuu, H.
- Affiliations
- Harvard University (US)
- Oregon Health & Science University (US)
- Fox Chase Cancer Center (US)
- Novartis (Switzerland) (CH)
- University of Helsinki (FI)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2002-08-15
- Volume
- 347
- Issue
- 7
- Pages
- 472-480
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2015015957
- Cited by
- 4,389
- References
- 21
- Citations by year
- 2026: 85 · 2025: 91 · 2024: 107 · 2023: 115 · 2022: 117 · 2021: 128 · 2020: 136 · 2019: 119 · 2018: 131 · 2017: 136 · 2016: 160 · 2015: 182 · 2014: 192 · 2013: 210 · 2012: 255
- FWCI
- 167.44
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- CRC Press eBooks (publishedVersion)
- PubMed (publishedVersion)
- Digital Access to Scholarship at Harvard (DASH) (Harvard University) (submittedVersion, cc-by)
- Funders
- U.S. Department of Veterans Affairs
- Northwest Health Foundation
- Helsingin Yliopisto
- Topics
- Health Sciences › Medicine › Gastroenterology › Gastrointestinal Tumor Research and Treatment
- Life Sciences › Immunology and Microbiology › Immunology › Mast cells and histamine
- Health Sciences › Medicine › Oncology › Gastric Cancer Management and Outcomes
- Keywords
- imatinib mesylate, gastrointestinal stromal tumor, KIT receptor tyrosine kinase, tyrosine kinase inhibitors, antitumor immunity, drug resistance, pharmacokinetics, adverse effects, metastatic cancer, dose comparison
- MeSH terms
- Imatinib Mesylate, Adolescent, Adult, Aged, Aged, 80 and over, Antineoplastic Agents, Benzamides, Female, Gastrointestinal Neoplasms, Humans, Male, Middle Aged, Piperazines, Protein-Tyrosine Kinases, Pyrimidines, Remission Induction, Signal Transduction, Survival Analysis, Stromal Cells, Proto-Oncogene Proteins c-kit
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.